FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1400-1405 November 4, 1993 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The frightening pace of the worldwide spread of the human immunodeficiency virus (HIV) demands that priority be placed on the development of an effective vaccine¹. Two distinct populations of viruses responsible for the acquired immunodeficiency syndrome (AIDS) have been defined: HIV type 2 (HIV-2), the viral group responsible for AIDS in West Africa, and HIV type 1 (HIV-1), the viral group that accounts for the AIDS epidemic in Central Africa and the rest of the world². The genomes of both HIV groups encode for three structural proteins: an envelope glycoprotein that constitutes the viral outer coat, a core . . . [Full Text of this Article]

Immune Responses to HIV in Infected Persons

Animal Models for Assessing Vaccine Strategies

Approaches to Vaccine Development

Traditional Approaches

Novel Approaches

Vaccine Trials in Humans

Future Studies

Discussion

Source Information

From the New England Regional Primate Research Center, Harvard Medical School, 1 Pine Hill Dr., P.O. Box 9102, Southborough, MA 01772-9102, where reprint requests should be addressed to Dr. Letvin.

References

This article has been cited by other articles:

• Seage III, G. R., Holte, S. E., Metzger, D., Koblin, B. A., Gross, M., Celum, C., Marmor, M., Woody, G., Mayer, K. H., Stevens, C., Judson, F. N., McKirnan, D., Sheon, A., Self, S., Buchbinder, S. P. (2001). Are US Populations Appropriate for Trials of Human Immunodeficiency Virus Vaccine? : The HIVNET Vaccine Preparedness Study. Am J Epidemiol 153: 619-627 [Abstract] [Full Text]  
• Park, E. J., Vujcic, L. K., Anand, R., Theodore, T. S., Quinnan, G. V. Jr. (1998). Mutations in both gp120 and gp41 Are Responsible for the Broad Neutralization Resistance of Variant Human Immunodeficiency Virus Type 1 MN to Antibodies Directed at V3 and Non-V3 Epitopes. J. Virol. 72: 7099-7107 [Abstract] [Full Text]  
• Letvin, N. L., Montefiori, D. C., Yasutomi, Y., Perry, H. C., Davies, M.-E., Lekutis, C., Alroy, M., Freed, D. C., Lord, C. I., Handt, L. K., Liu, M. A., Shiver, J. W. (1997). Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. USA 94: 9378-9383 [Abstract] [Full Text]  
• Farci, P., Shimoda, A., Wong, D., Cabezon, T., De Gioannis, D., Strazzera, A., Shimizu, Y., Shapiro, M., Alter, H. J., Purcell, R. H. (1996). Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. USA 93: 15394-15399 [Abstract] [Full Text]  
• Burton, D., Pyati, J, Koduri, R, Sharp, S., Thornton, G., Parren, P., Sawyer, L., Hendry, R., Dunlop, N, Nara, P., et, al. (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027 [Abstract]